Pharmacist intervention short ALSO adrs and drug drug interaction short

Reading File

Running Command

Reading File

Finding Sources

I now have all the information needed to write a thorough but concise response based on the case. Here is a complete analysis:

Pharmacist Intervention, ADRs & Drug-Drug Interactions

Case: CAD Patient - Adib Tahleel

Pharmacist Interventions

1. Dose Error - Tab Ecospirin labeled "Atorvastatin 150 mg" The prescription sheet lists "Tab Ecospirin" under generic name "Atorvastatin 150 mg" - this is a clear documentation/labeling error. Ecospirin is Aspirin (acetylsalicylic acid), not atorvastatin. The pharmacist must:

Clarify with the prescriber: is the intent aspirin (75 mg, standard antiplatelet for CAD) or atorvastatin (already separately prescribed as Tab Atorvas 40 mg)?
There is no standard 150 mg dose for either drug in this context. Aspirin for CAD is 75 mg/day.
Action: Flag, clarify, and correct before dispensing. Dispensing 150 mg atorvastatin would be a 3.75x overdose of the statin already being given.

2. Duplicate Therapy - Two Statin Entries Tab Ecospirin (listed as Atorvastatin) + Tab Atorvas (Atorvastatin 40 mg) - if both were atorvastatin, this is therapeutic duplication.

Action: Confirm Ecospirin = Aspirin 75 mg; ensure only one statin (Atorvas 40 mg) is continued.

3. Antihypertensive Selection - Prazosin as sole agent The patient's BP rose from 110/79 → 130/90 over 3 days. Prazosin (alpha-1 blocker) is not a first-line agent for CAD-related hypertension. Guidelines recommend ACE inhibitors/ARBs, beta-blockers, or CCBs.

Patient counselling sheet mentions Tab Telma (Telmisartan 40/25 mg) - but this drug is NOT on the hospital prescription chart. The counselling card and the in-hospital treatment are inconsistent.
Action: Reconcile the medication list; advocate for evidence-based antihypertensive (beta-blocker or ACE-I/ARB) for CAD.

4. Missing Antiplatelet Therapy Aspirin (75-100 mg/day) is the cornerstone of CAD secondary prevention. If Ecospirin is indeed aspirin, the dose and indication must be confirmed and documented clearly.

5. Low Potassium (K+ = 3.1 mEq/L - Hypokalemia) Patient's potassium is below normal (3.5-5 mEq/L). No potassium supplementation is prescribed.

Action: Recommend potassium supplementation or dietary counselling; monitor ECG (hypokalemia increases risk of arrhythmia, especially combined with ondansetron QT effects).

6. Elevated Eosinophils (12% - Normal: 0-8%) May indicate a drug hypersensitivity reaction or allergic process. Worth monitoring after ceftriaxone initiation.

Action: Monitor for hypersensitivity reactions; document as a signal.

7. Mild LFT Elevation (AST 40.2, ALT 38.9) Both slightly above normal (0-35 U/L), with statin therapy ongoing.

Action: Baseline LFTs should be rechecked after 6-8 weeks of statin use; advise physician if values worsen.

8. Diagnosis-Treatment Mismatch Chief complaint is slurring of speech + mouth deviation + right-sided weakness (classic stroke presentation), yet diagnosis is "Coronary Artery Disease." CT brain was ordered. The pharmacist should flag this discrepancy - a stroke workup (anticoagulation, antiplatelet) may be more appropriate than CAD management alone.

Adverse Drug Reactions (ADRs)

Drug	Key ADRs
Atorvastatin (40 mg)	Myalgia, muscle weakness, rhabdomyolysis (rare), elevated LFTs/hepatotoxicity, headache, GI upset
Pantoprazole (40 mg IV)	Hypomagnesemia with prolonged use, C. difficile risk, B12 deficiency (long term), headache
Ondansetron (4 mg IV)	QT prolongation (most significant - requires ECG monitoring), headache, constipation, serotonin syndrome
Ceftriaxone (1 g IV)	Hypersensitivity reactions (rash, anaphylaxis), biliary sludge/pseudolithiasis, elevated LFTs, diarrhea
Prazosin (1 mg BD)	First-dose phenomenon (orthostatic hypotension, syncope, dizziness), palpitations, edema
Calcium Carbonate	Hypercalcemia (high doses), constipation, milk-alkali syndrome
Calcium Pantothenate	Generally well tolerated; mild GI upset at high doses
Multivitamin	Generally safe; GI upset if taken on empty stomach

Atorvastatin ADRs: "Best recognized adverse effects include muscle pain, fatigue, weakness, and rhabdomyolysis... may be due to inhibition of heme A and ubiquinone synthesis, essential for oxidative phosphorylation." - Lippincott Biochemistry, 8th ed.

Ondansetron: "QT prolongation, QRS widening, constipation" - Harriet Lane Handbook, 23rd ed.

Prazosin: "'First-dose phenomenon' - faintness, dizziness, palpitation, and infrequently syncope, caused by acute postural hypotension." - Campbell Walsh Wein Urology

Drug-Drug Interactions (DDIs)

Drug Pair	Interaction	Severity
Atorvastatin + Calcium Carbonate	Calcium can adsorb some statins; separate administration by 2 hours recommended	Minor
Atorvastatin + Ceftriaxone	Ceftriaxone (mild CYP enzyme effects) - not a major DDI, but watch LFTs	Minor
Ondansetron + Any QT-prolonging drug	Additive QT prolongation risk; watch especially with hypokalemia (patient's K+ = 3.1)	Moderate-Major
Prazosin + Pantoprazole	PPIs can slightly increase prazosin bioavailability - monitor BP	Minor
Calcium Carbonate + Multivitamin (iron/zinc)	Calcium competes with iron/zinc absorption - separate timing	Minor
Atorvastatin + CYP3A4 inhibitors (if co-prescribed)	Risk of statin toxicity/myopathy - not in current list but watch if antibiotics like erythromycin are added	Potential

Most clinically significant interaction in this patient:

Hypokalemia (K+ 3.1) + Ondansetron IV - Low potassium exacerbates ondansetron-induced QT prolongation, increasing the risk of cardiac arrhythmias. This needs to be corrected urgently before ondansetron is continued.

Goodman & Gilman's: Pantoprazole has fewer drug interactions via CYP2C19 compared to other PPIs (omeprazole), making it the preferred PPI when co-prescribing drugs like clopidogrel.

Summary Table: Pharmacist's Priority Actions

Priority	Issue	Action
🔴 High	Ecospirin labeled as "Atorvastatin 150 mg"	Clarify & correct - likely Aspirin 75 mg
🔴 High	Hypokalemia + Ondansetron IV	Correct K+ first; ECG monitoring
🟠 Medium	Prazosin not first-line for CAD-HTN	Suggest beta-blocker or ACE-I/ARB
🟠 Medium	Telma on counselling but absent from prescription	Medication reconciliation needed
🟡 Low	Mild LFT elevation on statin	Repeat LFTs at 6-8 weeks
🟡 Low	Eosinophilia	Monitor for drug hypersensitivity

Could you clarify what you need? For example:

Did something look wrong or incomplete in the previous answer?
Do you want it shorter/simpler?
Do you have a specific question about the case?

Make a pharmacist intervention report (Word doc) summarizing the issues

Reading File

Running Command

Writing File

Running Command

The document is a valid .docx file. Here it is:

Pharmacist Intervention Report CAD

Word Document · DOCX

The report includes 7 sections:

Patient Information - summary table of vitals, complaints, diagnosis
Prescribed Medications - full drug chart with the Ecospirin error flagged in red
Pharmacist Interventions - 7 interventions with priority level and recommended actions
ADRs - table covering all 6 major drugs
Drug-Drug Interactions - 5 interactions with severity and action
Priority Action Summary - color-coded table (High/Medium/Low)
Patient Counselling Points - discharge guidance

All formatted with blue/white headers, alternating row shading, and page footers with your name and institution.

This is a shared conversation. Sign in to Orris to start your own chat.